Christine Xu

Ms. Christine Xu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Viruses
Verified
Journal Article
Open access
PDF file
CXChristine Xu
Christine Xu
MRMerry Z. C. Ruan
Merry Z. C. Ruan
VMVinit B. Mahajan
Vinit B. Mahajan
STStephen Tsang
Stephen Tsang
The frontiers of precision medicine have been revolutionized by the development of Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)/Cas9 as an editing tool. CRISPR/Cas9 has been used to develop animal models, understand disease mechanisms, and validate treatment targets. In addition, it is regarded as an effective tool for genome surgery when combined with viral delivery vectors. In this article, we will explore the various viral mechanisms for delivering CRISPR/Cas9 into tissues and cells, as well as the benefits and drawbacks of each method. We will also review the history and recent development of CRISPR and viral vectors and discuss their applications as a powerful tool in furthering our exploration of disease mechanisms and therapies.

1 September 2018 in Ophthalmology
Verified
Journal Article
Closed access
YTYi-Ting Tsai
Yi-Ting Tsai
WWWen-Hsuan Wu
Wen-Hsuan Wu
TLTing-Ting Lee
Ting-Ting Lee
WWWei-Pu Wu
Wei-Pu Wu
CXChristine Xu
Christine Xu
STStephen Tsang
Stephen Tsang

26 November 2018 in Genes
Verified
Journal Article
Open access
PDF file
DJDavid Jiang
David Jiang
CXChristine Xu
Christine Xu
STStephen Tsang
Stephen Tsang
Recently, there have been revolutions in the development of both gene medicine therapy and genome surgical treatments for inherited disorders. Much of this progress has been centered on hereditary retinal dystrophies, because the eye is an immune-privileged and anatomically ideal target. Gene therapy treatments, already demonstrated to be safe and efficacious in numerous clinical trials, are benefitting from the development of new viral vectors, such as dual and triple adeno-associated virus (AAV) vectors. CRISPR/Cas9, which revolutionized the field of gene editing, is being adapted into more precise “high fidelity” and catalytically dead variants. Newer CRISPR endonucleases, such as CjCas9 and Cas12a, are generating excitement in the field as well. Stem cell therapy has emerged as a promising alternative, allowing human embryo-derived stem cells and induced pluripotent stem cells to be edited precisely in vitro and then reintroduced into the body. This article highlights recent progress made in gene therapy and genome surgery for retinal disorders, and it provides an update on precision medicine Food and Drug Administration (FDA) treatment trials.

11 January 2019 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
VTVitor K. L. Takahashi
Vitor K. L. Takahashi
JTJúlia T. Takiuti
Júlia T. Takiuti
JCJose R. L. Carvalho-Jr
Jose R. L. Carvalho-Jr
CXChristine Xu
Christine Xu
JDJimmy K. Duong
Jimmy K. Duong
STStephen Tsang
Stephen Tsang

13 January 2018 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
KPKaren Sophia Park
Karen Sophia Park
CXChristine Xu
Christine Xu
XCXuan Cui
Xuan Cui
STStephen Tsang
Stephen Tsang

1 August 2018 in Molecular Therapy
Verified
Journal Article
Open access
LZLijuan Zhang
Lijuan Zhang
XCXuan Cui
Xuan Cui
RJRuben Jauregui
Ruben Jauregui
KPKaren Sophia Park
Karen Sophia Park
SJSally Justus
Sally Justus
STStephen Tsang
Stephen Tsang
Microglia cells (MGCs) play a key role in scavenging pathogens and phagocytosing cellular debris in the central nervous system and retina. Their activation, however, contributes to the progression of multiple degenerative diseases. Given the potential damage created by MGCs, it is important to better understand their mechanism of activation. Here, we explored the role of MGCs in the context of retinitis pigmentosa (RP) by using four independent preclinical mouse models. For therapeutic modeling, tamoxifen-inducible CreER was introduced to explore changes in MGCs when RP progression halted. The phenotypes of the MGCs were observed using live optical coherence tomography, live autofluorescence, and immunohistochemistry. We found that, regardless of genetic background, MGCs were activated in neurodegenerative conditions and migrated beyond the layers where they are typically found to the inner and outer segments, where degeneration was ongoing. Genetic rescue not only halted degeneration but also deactivated MGCs, regardless of whether the intervention occurred at the early, middle, or late stage of the disease. These findings suggest that halting long-term disease progression may be more successful by downregulating MGC activity while co-administering the therapeutic intervention.